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CoA-dependent activation of mitochondrial acyl
carrier protein links four neurodegenerative diseases
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Abstract
PKAN, CoPAN, MePAN, and PDH-E2 deficiency share key phenotypic
features but harbor defects in distinct metabolic processes. Selec-
tive damage to the globus pallidus occurs in these genetic
neurodegenerative diseases, which arise from defects in CoA
biosynthesis (PKAN, CoPAN), protein lipoylation (MePAN), and pyru-
vate dehydrogenase activity (PDH-E2 deficiency). Overlap of their
clinical features suggests a common molecular etiology, the identi-
fication of which is required to understand their pathophysiology
and design treatment strategies. We provide evidence that CoA-
dependent activation of mitochondrial acyl carrier protein (mtACP)
is a possible process linking these diseases through its effect on
PDH activity. CoA is the source for the 40-phosphopantetheine
moiety required for the posttranslational 40-phosphopantetheiny-
lation needed to activate specific proteins. We show that impaired
CoA homeostasis leads to decreased 40-phosphopantetheinylation
of mtACP. This results in a decrease of the active form of mtACP,
and in turn a decrease in lipoylation with reduced activity of lipoy-
lated proteins, including PDH. Defects in the steps of a linked CoA-
mtACP-PDH pathway cause similar phenotypic abnormalities. By
chemically and genetically re-activating PDH, these phenotypes
can be rescued, suggesting possible treatment strategies for these
diseases.
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Introduction
Coenzyme A (CoA) is an essential cofactor participating in approxi-
mately 9% of all cellular metabolic reactions, such as the tricar-
boxylic acid (TCA) cycle, and fatty acid synthesis and degradation
(Leonardi et al, 2005; Strauss, 2010). CoA is synthesized de novo in
cells, utilizing vitamin B5 as a starting molecule and requiring five
enzymatic reactions. These are carried out by pantothenate kinase
(PANK), phosphopantothenoylcysteine synthetase (PPCS), phospho-
pantothenoylcysteine decarboxylase (PPCDC), phosphopantetheine
adenylyltransferase (PPAT), and dephospho-CoA kinase (DPCK),
respectively (Leonardi et al, 2005; Strauss, 2010). In some organ-
isms, including Drosophila melanogaster, mice, and humans, PPAT
and DPCK enzyme activities are performed by a single bifunctional
protein, referred to as CoA synthase or COASY (Fig 1). The interme-
diate products that are being sequentially formed from vitamin B5
during the CoA de novo biosynthesis pathway are as follows: 40-
phosphopantothenate, 40-phosphopantothenoylcysteine, 40-phospho-
pantetheine, dephospho-CoA, and CoA (Fig 1). Enzymes of the
CoA de novo biosynthesis pathway are evolutionarily conserved,
further underscoring the importance of this pathway for all living
organisms.
Two autosomal recessive neurodegenerative diseases are
caused by mutations in genes encoding enzymes of the CoA path-
way. Pathogenic variants in PANK2 and COASY lead to two early-
onset neurodegenerative diseases: pantothenate kinase-associated
neurodegeneration (PKAN) and CoA synthase protein-associated
neurodegeneration (CoPAN). The human genome contains four
genes encoding pantothenate kinase homologs, PANK1-4, and
only mutations in PANK2 are associated with PKAN. PKAN and
CoPAN patients accumulate iron in the globus pallidus, a basal
ganglia structure in the brain (Hayflick et al, 2003; Dusi et al,
2014). Iron accumulation is visible on T2-weighted imaging as a
hypointense signal on MRI. In PKAN and CoPAN areas, T2-hyper-
intense signals are also seen at the globus pallidus, indicating
edema and tissue damage (Kruer et al, 2012). These CoA-linked
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diseases are characterized by progressive motor dysfunction and
severe dystonia.
Damage to the globus pallidus occurs in other inborn errors of
metabolism as well. MePAN, a third childhood-onset neurodegener-
ative disorder, manifests with damage to the globus pallidus, which
is also visible on brain MRI as hyperintense signal on T2-weighted
imaging although without the iron-associated signal abnormalities
(Heimer et al, 2016). MePAN patients carry mutations in the gene
encoding mitochondrial enoyl-[acyl-carrier-protein] reductase
(MECR), one of four enzymes involved in the elongation of fatty
acids in mitochondria to form octanoic acid, a precursor of lipoic
acid (Fig 1; Heimer et al, 2016). In eukaryotic cells, this process of
mitochondrial fatty acid synthesis (mtFAS-type II) is required for
lipoic acid production and subsequently for lipoylation of proteins
(Brody et al, 1997; Wada et al, 1997; Feng et al, 2009). Finally,
mutations causing impairment of a component of the pyruvate
dehydrogenase complex, PDH-E2, lead to PDH-E2 deficiency and
cause a form of Leigh disease, in which neuroradiographic abnor-
malities are again observed specifically in the globus pallidus (Head
et al, 2005; McWilliam et al, 2010; Leoni et al, 2012). PDH catalyzes
the oxidative decarboxylation of pyruvate to produce acetyl-CoA,
thereby linking glycolysis to the TCA cycle (Fig 1). The symptoms,
signs, and MRI characteristics of PKAN and PDH-E2 deficiency can
be similar. In patients with a clinical suspicion of PKAN, PDH-E2
deficiency should also be considered in the differential diagnosis
and vice versa (Head et al, 2005; McWilliam et al, 2010; Leoni et al,
2012). The clinical and neuroradiographic overlapping features of
PKAN, CoPAN, MePAN, and PDH-E2 deficiency suggest a common
element in their pathogeneses.
The pathways of CoA biosynthesis, mitochondrial fatty acid
synthesis, and glycolysis/TCA cycle show interdependency and
interconnectivity (Leonardi et al, 2005; Strauss, 2010; Beld et al,
2014; Kastaniotis et al, 2017; Fig 1), but a specific molecular etiol-
ogy common to these four disorders has been lacking.
Herein, we propose a common underlying pathway directly
connecting these four diseases. In most CoA-dependent metabolic
reactions, CoA acts as an acyl carrier; the acyl moiety is transferred
between CoA and another molecule (e.g., carnitine), leaving CoA
intact and available for further transfer reactions. CoA-dependent
acyl transfer occurs during the TCA cycle, fatty acid synthesis, and
fatty acid degradation (Fig 1). Because CoA is re-used as acyl carrier
component, these reactions do not lead to reduced levels of total
CoA. In contrast, one specific form of posttranslational modification
“consumes” CoA. 40-phosphopantetheinylation adds a 40-phospho-
pantetheine moiety to specific proteins resulting in their activation.
For this modification, the 40-phosphopantetheine moiety is derived
from CoA (Beld et al, 2014). Therefore, this reaction forms a 40-
phosphopantetheinylated protein, and adenosine 30,50-bisphosphate
is released and thereby causes a net loss of CoA (Elovson & Vagelos,
1968). In humans, a select group of proteins requires this 40-phos-
phopantetheine moiety in order to function, e.g. 10-formyltetrahy-
drofolate dehydrogenase, an enzyme of folate metabolism
(Strickland et al, 2010), cytosolic fatty acid synthase, and mitochon-
drial acyl carrier protein (mtACP; Joshi et al, 2003; Beld et al,
2014). We focussed on mtACP because human PANK2, COASY,
MECR, and PDH-E2 are mitochondrial proteins (Kotzbauer et al,
2005; Dusi et al, 2014) and mitochondria are defective in various
PKAN animal models (Rana et al, 2010; Brunetti et al, 2014; Orel-
lana et al, 2016; Jeong et al, 2019). The active 40-phosphopantethei-
nylated form of mtACP is referred to as holo-mtACP. mtACP, known
in humans as NDUFAB1, is one of the subunits of the respiratory
chain complex I and plays a central role in mitochondrial fatty acid
synthesis (Brody et al, 1997; Feng et al, 2009). In this latter process,
the thiol group of the 40-phosphopantetheine prosthetic group forms
the attachment site for a growing carbon chain (Beld et al, 2014).
Octanoate formed in this way is converted to lipoic acid and used
to modify mitochondrial proteins, among which are the E2 subunits
of three enzyme complexes (pyruvate dehydrogenase (PDH),
a-ketoglutarate dehydrogenase (aKGDH), branched-chain a-keto
acid dehydrogenase (BCKDH), and the glycine cleavage system
(GCV); Cronan, 2016; Rowland et al, 2018). In humans, octanoic
acid is transferred to its target proteins by the lipoyl transferases
◀ Figure 1. Metabolic pathways in which coenzyme A is formed, re-used, or consumed and their interconnections.A De novo biosynthesis pathway of coenzyme A (CoA) is a pathway during which CoA is produced. Vitamin B5 is taken up by cells and converted into CoA by the action
of five enzymatic reactions (Leonardi et al, 2005; Strauss, 2010). These are carried out by pantothenate kinase (PANK), phosphopantothenoylcysteine synthetase
(PPCS), phosphopantothenoylcysteine decarboxylase (PPCDC), phosphopantetheine adenylyltransferase (PPAT), and dephospho-CoA kinase (DPCK), respectively. In
Drosophila melanogaster, mice, and humans, PPAT and DPCK enzyme activities are carried out by a single bifunctional protein, CoA synthase or COASY. Abbreviations
of the enzymes are provided. The starting product vitamin B5/pantothenate, the intermediate, 40-phosphopantetheine, and the final product CoA are depicted. PKAN
and CoPAN are inherited recessive diseases caused by homozygous mutations in PANK2 and COASY, respectively.
B Formation of holo-mtACP (active form of mitochondrial acyl carrier protein) is a CoA consuming metabolic reaction (Beld et al, 2014). 40-phosphopantetheinylation of
inactive apo-mtACP is required to produce the active holo-mtACP form. During this process, CoA serves as the source for the 40-phosphopantetheinylation, and
hereby, a CoA molecule is degraded and adenosine 30–50-biphosphate is released. Holo-mtACP plays a key role in mitochondrial fatty acid synthesis, which can be
visualized in (C).
C Fatty acid synthesis is a metabolic pathway in which CoA is re-used (Kastaniotis et al, 2017). Mitochondrial fatty acid synthesis (mtFASII) is required for the synthesis
of lipoic acid, a pathway that is dependent on the activity of holo-mtACP. In this pathway, malonic acid is converted to malonyl-CoA, which requires holo-mtACP (or
NDUFABI in humans) for the formation of malonyl-holo-ACP as well as for subsequent downstream steps. Mitochondrial Enoyl-[acyl-carrier-protein] reductase (MECR,
defective enzyme in MEPAN) is required for the formation of acyl-holo-mtACP as indicated. Via this pathway lipoic acid is formed from octanoyl-holo-mtACP by lipoic
acid synthetase (LIAS). This product is then required for the formation of lipoylated pyruvate dehydrogenase (PDH), lipoylated a-ketoglutarate dehydrogenase
(aKGDH), lipoylated branched-chain alpha-keto acid dehydrogenase (BCKDH), and lipoylated glycine cleavage system (GCV). Lipoylation of the above-mentioned
proteins is necessary for catalysis of their respective reactions to occur.
D Fatty acid (FA) degradation or b-oxidation is an example of a degradation pathway in which CoA is re-used. The starting mitochondrial precursor acyl-carnitine, the
intermediates, and the end product of this pathway are indicated, as well as reactions in which CoA is required (but not consumed) and released.
E In the glycolysis and TCA cycle, CoA is re-used. Pyruvate dehydrogenase (PDH) catalyzes the oxidative decarboxylation of pyruvate to produce acetyl that is coupled to
CoA to produce acetyl-CoA. Impaired function of this enzyme leads to PDH-E2 deficiency. The product of the PDH reaction, acetyl-CoA, is the fuel for the TCA cycle
which is also a CoA re-using pathway as indicated. OAA: oxaloacetate.
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LIPT2 and LIPT1. By the action of the conserved enzyme lipoic acid
synthase (LIAS in humans), protein-bound octanoate is transformed
into lipoic acid (LA) by the insertion of two sulfhydryl groups
(Booker, 2004; Hiltunen et al, 2010; Solmonson & DeBerardinis,
2018), enabling the now-lipoylated proteins to function (Fig 1;
Hiltunen et al, 2010). Based on these reports, we hypothesized that,
because 40-phosphopantetheinylation of mtACP consumes CoA, this
reaction may be most sensitive to impaired CoA biosynthesis.
Consequently, downstream processes are predicted to be affected as
well, including decreased lipoylation and activity of PDH (Fig 2).
Figure 2. De novo CoA biosynthesis pathway and key downstream steps to link PKAN, CoPAN, MePAN, and PDH-E2 deficiency.
Left part: Proposed linear pathway linking CoA-mtACP-PDH. From top to bottom: The de novo CoA biosynthesis pathway starts with the cellular uptake of pantothenate
(Vitamin B5). Pantothenate kinase (PANK), phosphopantothenoylcysteine synthetase (PPCS), phosphopantothenoylcysteine decarboxylase (PPCDC), and coenzyme A
synthase (COASY) are enzymes required for the de novo biosynthesis of CoA. Mitochondrial acyl carrier protein (mtACP) undergoes a posttranslational modification and
active holo-mtACP is formed. This posttranslational modification consists of 40-phosphopantetheine, which is derived from CoA. Holo-mtACP in turn is required for
lipoylation of PDH-E2, amodification necessary for activation of the PDH complex. It is hypothesized that a decrease in CoA biosynthesis leads to decreased amounts of holo-
ACP, decreased lipoylation of PDH-E2, and decreased activity of PDH.Right part: Steps that are affected in PKAN, CoPAN, MePAN, and PDH-E2 deficiency. Primary affected
steps caused by the genetic defects are depicted as the most upstream steps as well as the hypothesized downstream steps for CoPAN, PKAN, and MePAN.
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This hypothesis could explain how defects in PANK2 and COASY
might lead to a phenotype similar to that arising from defects in
MECR and PDH (Fig 2). A central tenet of this hypothesis is that
impaired de novo biosynthesis of CoA leads to decreased levels of
holo-mtACP. Here, we investigated this hypothesis.
The de novo CoA biosynthesis pathway and the metabolic reac-
tions presented in Figs 1 and 2) are highly conserved between
human and Drosophila melanogaster (Leonardi et al, 2005; Bosveld
et al, 2008). Our combined approach employing the versatile genetic
tools of Drosophila melanogaster and mammalian cells enabled us
to demonstrate that impaired CoA biosynthesis leads to decreased
levels of active, 40-phosphopantetheinylated mtACP. This observa-
tion was associated with decreased lipoylation of PDH-E2 and
decreased PDH activity. Our results revealed the presence of a CoA-
mtACP-PDH pathway in which the 40-phosphopantetheinylation of
mtACP is a key step. Next, we showed that stimulation of PDH
rescued phenotypes caused by impaired CoA biosynthesis, high-
lighting PDH as a possible common target for ameliorating diseases
induced by defects in the CoA-mtACP-PDH pathway. Our findings
combined with those reported by Jeong et al suggest therapeutic
approaches for PKAN, CoPAN, MePAN, and PDH-E2 deficiency.
Results
holo-mtACP levels are reduced by impeding CoA biosynthesis
PKAN and CoPAN patients carry mutations in genes coding for
pantothenate kinase 2 and COASY, enzymes required for CoA
biosynthesis (Fig 1). To test our hypothesis (presented in Fig 2), we
first investigated consequences of impaired CoA biosynthesis on 40-
phosphopantetheinylation of mtACP. For this, we chose Drosophila
melanogaster because of its conserved metabolic steps and genes
and its versatile genetic tools. mtACP requires activation in order to
function; the active holo form is generated by enzymatic transfer of
a negatively charged 40-phosphopantetheine moiety to a conserved
serine residue of the inactive apo form (Elovson & Vagelos, 1968;
Jung et al, 2016; Fig 3A). For our study we manipulated mtacp, the
Drosophila melanogaster gene encoding mtACP, containing Ser-99,
which is predicted to bind 4-phosphopantetheine (Ragone et al,
1999). In order to be able to identify and distinguish the two forms
of mtACP (holo versus apo), we generated constructs encoding
mutant proteins that would be refractory to 4-phosphopantetheiny-
lation and observed their mobility differences using gel elec-
trophoresis. We mutated the crucial serine residue: one to mimic
the uncharged apo form (S99A) and two negatively charged forms
(S99D and S99E) to mimic the charged holo form of mtACP
(Fig 3A). Overexpression of wild-type mtACP constructs in Droso-
phila S2 Schneider cells enabled the visualization of protein bands
that correspond to endogenous apo- and holo-mtACP forms. By
comparing these bands to the apo-mimetic S99A and holo-mimetics
S99D and S99E, we were able to prove the identity of the bands
visualized under control and mtACP wild-type overexpressing
conditions. Under physiologic conditions, endogenous holo-mtACP
was detected (Fig 3B and C). In contrast, no endogenous apo-
mtACP protein was visible, consistent with previous observations in
other organisms that the inactive apo-mtACP form is not stable
(Jackowski & Rock, 1983; Post-Beittenmiller et al, 1989).
We proceeded to investigate whether levels of active holo-mtACP
would decrease upon CoA deprivation, a key assumption of our
hypothesis. Treating S2 cells with the PANK inhibitor hopantenate
(HoPan) leads to reduced CoA biosynthesis and to reduced levels of
total CoA (Rana et al, 2010; Siudeja et al, 2011; Srinivasan et al,
2015). Under these conditions, we observed reduced levels of
endogenous holo-mtACP (Fig 3C), and addition of CoA to the
medium of HoPan-treated cells reverted this phenotype, consistent
with previous studies in which administration of extracellular CoA
is able to rescue phenotypes associated with reduced intracellular
CoA biosynthesis (Rana et al, 2010; Siudeja et al, 2011; Srinivasan
et al, 2015). These results demonstrate that impaired CoA biosyn-
thesis is associated with decreased levels of 40-phosphopantetheiny-
lation of mtACP.
Protein lipoylation is reduced by impeding CoA biosynthesis
To further investigate the consequences of impaired CoA biosynthe-
sis and reduced levels of 40-phosphopantetheinylated mtACP, we
examined mtACP-dependent processes, specifically those linked to
MePAN and PDH-E2 deficiency. holo-mtACP and MECR are required
for protein lipoylation (Fig 1), a process that is therefore affected in
MePAN patients (Heimer et al, 2016). Four evolutionary conserved
lipoylated enzyme complexes have been identified: PDH, a-KGDH,
BCKDH, and GCV. To assess whether lipoylation was affected under
conditions of impaired CoA biosynthesis, total protein lipoylation
was analyzed using Western blot analysis. Incubation with an anti-
body that detects protein-bound lipoic acid revealed decreased
levels of various protein bands under conditions of reduced CoA
levels, an effect that was rescued when CoA was supplemented to
the medium (Fig 3D, Appendix Fig S1). The availability of an anti-
body recognizing the Drosophila PDH-E2 subunit allowed the analy-
sis of lipoylated PDH-E2 specifically, demonstrating that lipoylation
of PDH-E2 was compromised in a CoA reduced background
compared to control levels, an effect that was rescued by replenish-
ing CoA (Fig 3D and E). Specific antibodies for the other lipoylated
fly enzymes are lacking, but the observation that total protein lipoy-
lation is reduced under conditions of impaired CoA biosynthesis
suggests that the other lipoylated fly enzymes are similarly affected.
Pyruvate dehydrogenase activity decreases upon CoA deprivation
Because we were able to specifically document decreased PDH
lipoylation under reduced CoA biosynthesis conditions, we
predicted that PDH enzyme activity would be decreased. Lipoylation
of PDH-E2 is essential for the subunit and complex to function, as
the lipoyl moiety binds and oxidizes the hydroxyl-ethyl compound
derived from pyruvate and subsequently transfers it to its acceptor
CoA to generate acetyl-CoA (Patel et al, 2014). To determine
whether CoA deprivation indeed decreases PDH activity, we quanti-
fied PDH activity in control S2 cells and cells treated with HoPan
(Fig 3F). We observed a significant reduction in PDH activity upon
HoPan treatment compared to control cells, an effect rescued by
addition of CoA to the HoPan-treated cells (Fig 3F). We assumed
that, in the HoPan-treated cells, a fraction of the remaining pool of
lipoylated PDH is partly inactivated by the presence of the endoge-
nous PDH-inhibitor pyruvate dehydrogenase kinase (PDK). There-
fore, we predicted that residual PDH activity could be increased by
ª 2019 The Authors EMBO Molecular Medicine e10488 | 2019 5 of 21
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interfering with the action of this inhibitory enzyme. To test this,
we added dichloroacetate (DCA) to the medium of the HoPan-
treated cells. DCA is a clinically used drug (Stacpoole et al, 1983,
1992) that inhibits the PDH inhibitor, PDK (Walsh et al, 1976; Patel
& Korotchkina, 2006), and as such leads to activation of PDH
(Whitehouse et al, 1974). Addition of DCA indeed caused an
increase in PDH activity compared to HoPan-treated cells (Fig 3F).
These results indicate that the pyruvate dehydrogenase complex is
functionally impaired as a consequence of CoA biosynthesis inhibi-
tion and under these circumstances can still be activated by DCA.
These data support the existence of a CoA-mtACP-PDH pathway
(Fig 2).
Direct stimulation of PDH rescues phenotypes induced by
dPANK/fbl knockdown in vivo
Our next step was to investigate a causal connection between CoA
dyshomeostasis and PDH activity in a multicellular organism, Droso-
phila melanogaster, by asking whether phenotypes induced by
impaired CoA biosynthesis could be rescued by recovery of PDH
activity. To test this in whole organisms and complement our stud-
ies in Drosophila S2 cells, we used a genetic approach in flies,
employing the binary UAS/GAL4 system (Brand & Perrimon, 1993;
Dietzl et al, 2007) to knockdown dPANK/fbl using RNAi. dPANK/fbl
is the Drosophila ortholog of human PANK2 (Afshar et al, 2001;
Bosveld et al, 2008). In contrast to mammals, Drosophila possesses
only one pank gene (Afshar et al, 2001). However, this gene gives
rise to several pank isoforms, among which is one that localizes to
mitochondria (Wu et al, 2009). Ubiquitous expression of a dPANK/
fbl-RNAi construct in all tissues of the fly using an actin promotor
resulted in significantly decreased dPANK/fbl mRNA and protein in
two independent lines (Fig 4A, Appendix Fig S2), demonstrating the
effectiveness of the RNAi constructs. Downregulation of dPANK/fbl
resulted in fewer flies that reached the adult stage compared to
control flies (Fig 4B, Appendix Fig S3). Impairment of dPANK/fbl in
Drosophila results in decreased total CoA levels and reduced viabil-
ity (Rana et al, 2010; Srinivasan et al, 2015). Addition of pantethine
to the fly food, which restores total CoA levels in a dPANK/fbl-
deprived background (Rana et al, 2010), fully restored their viabil-
ity, further confirming the CoA dependency of this phenotype
(Fig 4B). Next we investigated whether stimulation of PDH in the
dPANK/fbl knockdown flies increased their viability as well. For
this, we added DCA to the fly food and consistent with the results
obtained from S2 cells, a dose-dependent restoration of viability was
observed (Fig 4B). These results suggest that viability can be recov-
ered by boosting the activity of PDH.
Downregulation of key steps of the CoA-PDH pathway during
development causes a common abnormal morphogenetic
phenotype in Drosophila wings
The dose-dependent rescue by DCA of the dPANK/fbl knockdown
phenotype provides evidence that deleterious phenotypes associated
with CoA deprivation are at least partially mediated via decreased
activity of PDH. The proposed pathway (Fig 2) further predicts that
impairment of individual components of this pathway would cause
a phenotype with overlapping characteristics. To investigate this,
we created a genetically and phenotypically tractable system. Using
tissue-specific RNAi-mediated knockdown of various genes along
the CoA-mtACP-PDH pathway, we selected the wing as our target
tissue. Visible details of wing structure and morphogenesis are well-
delineated and provide a robust and quantifiable phenotypic read-
out. Importantly, disruption of metabolism in specific cells of the
developing wing does not cause lethality of the organism, as is
common when critical metabolic pathways are disrupted in other
organ systems or in whole organisms. During early Drosophila
◀ Figure 3. Decreased levels of CoA are associated with decreased levels of holo-mtACP and lipoylated PDH-E2.A Schematic presentation of endogenous active and inactive forms of mtACP and synthesized mutant forms of mtACP. For the endogenous form, the S represents the
serine residue that is 40-phosphopantetheinylated, while D and L represent the flanking amino acids. Inactive form of mtACP (apo-mtACP) is indicated with 1. CoA is
the source for 40-phosphopantetheine and is required for 40-phosphopantetheinylation of mtACP occurring on the serine residue. This posttranslational modification
results in an active form of mtACP, holo-mtACP, which is negatively charged and indicated with 2. Three mtACP constructs were generated: One in which serine 99
was modified to an alanine, indicated with a 3 and indicated as S99A (non-40-phosphopantetheinylatable form); one in which serine 99 was modified into aspartate,
indicated with a 4 and indicated as S99D (phosphomimetic); one in which serine 99 was modified into glutamate, indicated with a 5 and indicated as S99E
(phosphomimetic). S99D and S99E are negatively charged, mimicking the negatively charged holo-mtACP. The red circle indicates the presence of a negative charge.
B Western blot analysis of S2 cells overexpressing wild-type constructs of mtACP or the various mutant forms. First lane: lysates of control cells, resulting in the
detection of holo-mtACP visible after long exposure. Second lane: overexpression (OE) of mtACP WT results in the detection of an apo-mtACP form and a holo-mtACP
form, indicated with 1 and 2, respectively. Third lane: overexpression of mtACP S99A mutant form resulted in the detection of an apo-mtACP (non-40-
phosphopantetheinylatable) band only, indicated with 3. Fourth lane: overexpression of mtACP S99D resulted in the detection of a phosphomimetic form of mtACP
only, migrating at the same mobility as holo-mtACP, indicated with 4. Fifth lane: overexpression of mtACP S99E results in the detection of a phosphomimetic form of
mtACP only, migrating at the same mobility as holo-mtACP, indicated with 5. For visualization, a low exposure and high exposure blot are shown. Note that
overexposed blots were required to visualize endogenous forms of mtACP.
C Western blot analysis of mtACP forms under control conditions, under conditions of HoPan treatment, and under conditions of HoPan + CoA treatment. Lanes
showing overexpression of mtACP WT, mtACP S99A, and mtACP S99D were used to allow identification of the holo- and the apo-forms of mtACP. a-Tubulin was used
as a loading control. Various exposure times of the blots are presented to allow identification of mtACP under all conditions.
D Western blot analysis showing lipoylated proteins under control conditions, after HoPan treatment and after HoPan + CoA treatment. S2 cells were treated with
HoPan or HoPan + CoA for 4 days; non-treated cells were used as control. Antibodies specifically recognizing lipoylated proteins or PDH-E2 were used. Arrow heads
indicate lipoylated PDH-E2 (left panel) or total PDH-E2 (right panel).
E Quantification of lipoylated PDH-E2 from (D). Mean  SD is given. n = 3 for all samples.
F PDH activity was measured in control cells, HoPan-treated cells or HoPan-treated cells rescued with CoA or DCA. Mean  SD of five biological replicates, each
composed of three technical replicates and corrected for protein concentration.
Data information: For (E and F), two-tailed Student’s t-test was performed to calculate statistical significance for the indicated subsets.
Source data are available online for this figure.
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embryogenesis wing imaginal discs are formed, growing in size
during later larval stages and finally forming adult wings during
metamorphosis (Appendix Fig S4). Specific parts of the imaginal
wing discs develop into specific parts of the adult wing. The larval
hinge develops into the adult hinge and the larval wing pouch devel-
ops into the adult wing blade forming the majority of the wing struc-
ture (Appendix Fig S4; Diaz de la Loza & Thompson, 2017).
Disruption of specific genes in parts of the wing during development
leads to macroscopically visible wing abnormalities in the adult fly
that can be readily scored. A plethora of mutant adult wing pheno-
types have been reported, including holes, notches, vein abnormali-
ties, blisters, increased/decreased size, and several others of the
wing blade, depending on the specific gene that has been targeted
by the RNAi (Bejarano et al, 2012).
We performed wing-specific RNAi-mediated knockdown of
several components of the CoA-mtACP-PDH pathway during the
larval stage. For this, we selected dPANK/fbl and dPPCDC/ppcdc
(the first and third enzyme of the CoA biosynthesis pathway
(Bosveld et al, 2008) and mtacp (Drosophila mtACP, Ragone et al,
1999). For these genes, Drosophila lines harboring RNAi constructs
were available, and efficient knockdown could be demonstrated
using a wing pouch-specific expression driver (Appendix Fig S4).
Downregulation of dPANK/fbl, dPPCDC/ppcdc, or mtacp in the
developing larval wing discs leads to a clearly distinguishable wing
phenotype in the adult flies, characterized by size decrease and
fluid-filled wing blisters varying in size (Fig 5A, C, E and H;
Bejarano et al, 2012). The severity of the blister phenotype varied
between the knockdowns, most likely because of variations in
effectivity of the individual RNAi constructs. This is further
substantiated because co-expression of the RNAi-enhancing
element dcr2 with the RNAi construct of each of the three genes
resulted in a stronger phenotype (Fig 5B, D, F and I). Combined
RNAi-mediated knockdown of both dPANK/fbl and dPPCDC/ppcdc
resulted in an increase of the blistering phenotype (Fig 5G)
compared to that arising from downregulation of the single
constructs alone (Fig 5C and E). This observation is consistent
with the idea of incomplete RNAi-mediated knockdown of either
component and suggests an additive phenotype. Together, these
experiments validate the genetic knockdown system and implicate
a common underlying cellular defect along the CoA-mtACP-PDH
pathway leading to a similar phenotype, when the individual steps
are compromised.
Genetic and pharmacologic stimulation of the pyruvate
dehydrogenase complex rescues wing phenotypes caused by
impaired CoA synthesis
The observation that knockdown of the individual genes dPANK/fbl,
dPPCDC/ppcdc, and mtacp cause a phenotype with overt similarities
is suggestive for the presence of an underlying common cellular
defect. To substantiate this further, we investigated whether boost-
ing PDH activity would rescue the wing-blister phenotype induced
A B
Figure 4. Downregulation of dPANK/fbl induces decreased viability of adult flies, which is rescued by pantethine and DCA treatment.
A Decreased dPANK/Fbl protein levels were determined in two independent dPANK/fbl-RNAi strains (1 and 2), in which dPANK/fbl-RNAi was ubiquitously expressed. A
wild-type strain was used as a control. An anti-dPANK/Fbl antibody was used to detect protein levels with Western blot analysis on whole fly extracts. Tubulin was
used as a loading control.
B Survival rate of adult flies was determined for dPANK/fbl-RNAi flies, compared to control flies under normal food conditions and after the supplementation of
dichloroacetate (DCA) or pantetheine to the food. The assay is explained and visualized in Appendix Fig S3. dPANK/fbl-RNAi flies show a decreased survival rate
compared to control flies. DCA and pantetheine when added to the food increased viability of dPANK/fbl-RNAi flies. Total number of flies used for each group is
indicated above each bar. Statistical analyses were carried out using Fisher’s exact test.
Source data are available online for this figure.
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by impaired CoA biosynthesis, comparable to the improved viability
we showed in the dPANK/fbl-RNAi flies. To investigate this we used
the Drosophila line with the wing-specific downregulation of
dPPCDC/ppcdc, in which the blistering phenotype is highly pene-
trant (in approximately 85% of the adult flies; Fig 6A). We assumed
that, in the affected wing, comparable to the HoPAN-treated cells, a
fraction of the remaining pool of lipoylated PDH is partly inactivated
by the presence of the endogenous PDH-inhibitor pyruvate dehydro-
genase kinase (PDK). In addition, PDH can be inactivated by
endogenous SIRT4, a lipoamidase that also inhibits PDH (Mathias
et al, 2014). Therefore, we predicted that residual PDH activity
could be increased by interfering chemically or genetically with the
action of these inhibitory enzymes (Fig 6B and C). Indeed, we found
that feeding the larvae DCA (PDK inhibitor) resulted in a dose-
dependent decrease of wing blisters in the adult flies (Fig 6A). In
addition, a genetic approach was used (Fig 6C, right part) to
decrease the expression of PDK and SIRT4, by RNAi-mediated
knockdown using two different lines per target. The knockdown
efficacy of these constructs was verified and they were confirmed to
cause no apparent phenotype in control flies (Appendix Fig S5). As
predicted, downregulation of these PDH-inhibitors by RNAi in the
dPPCDC/ppcdc-depleted background partly resolved the wing-blister
phenotype (Fig 6D). Non-specific genetic effects were excluded by
using an RNAi line, unrelated to this pathway and from the same
Drosophila RNAi library. This unrelated RNAi line in the dPPCDC/
ppcdc-depleted background did not affect the blister phenotype
(Appendix Fig S6). These results showing that boosting PDH activity
can dampen the deleterious effects of impaired CoA biosynthesis
and further establish the connection between CoA production and
PDH activity.
Downregulation of PANK2, the defective gene in PKAN, leads to a
decrease in mtACP in human cells
Our results in Drosophila show that defects in CoA biosynthesis lead
to a decrease in holo-mtACP levels and decreased lipoylation and
activity of PDH, suggesting that a final common pathway through
PDH may explain the overlapping phenotypic features of PKAN,
CoPAN, MePAN, and PDH-E2 deficiency. Several findings in
mammalian systems further support our hypothesis: decreased PDH
activity was recently demonstrated in a true PKAN mouse model by
Jeong et al (2019) and decreased lipoylation of PDH was demon-
strated in MePAN patient fibroblasts (Heimer et al, 2016). While
these findings support our hypothesis, a key player in this pathway,
mtACP has not been investigated in mammalian systems with
impaired PANK2 activity. Therefore, we generated HEK293T (hu-
man embryonal kidney, Appendix Fig S7) and SH-SY5Y (human
neuroblastoma, Appendix Fig S8) cells in which PANK2 protein
levels were downregulated. We generated two independent clones
per cell line in which, PANK2-RNAi expression was inducible by
addition of doxycycline and this led to decreased PANK2 protein.
Efficiency of PANK2 downregulation was verified using Western
blot and qPCR analysis. This demonstrated that PANK2 protein
levels were undetectable in both cell lines, whereas PANK1,
PANK3, and PANK4 RNA levels were unchanged, establishing the
specificity of the PANK2 RNAi constructs (Fig 7A and C,
Appendix Figs S9 and S10). Downregulation of the Drosophila
dPANK/fbl gene is associated with an actual decrease in total CoA
levels (Rana et al, 2010; Srinivasan et al, 2015), explaining the
observed decrease in 40-phosphpantetheinylation of mtACP. There-
fore, we sought to determine whether downregulation of PANK2 in
the generated clones led to a measurable decrease in total CoA
levels. Total CoA levels were not significantly decreased in any cell
lines compared to the controls after 10 days of RNAi treatment
despite clear evidence of PANK2 protein loss (Fig 7E and F,
Appendix Fig S11). Our results do not exclude the possibility that
specific subcellular compartmental CoA levels may be decreased in
these cells. Next we determined levels of human mtACP under
conditions of downregulation of human PANK2. Levels of mtACP
were significantly reduced in both PANK2-depleted neuroblastoma
cell lines and in one of the two PANK2-depleted HEK293 cell lines
compared to controls (Fig 7A–D). Since apo-mtACP is unstable
and not detectable in other systems, the observed signal for mtACP
is most likely the holo-(activated form of mtACP; Jackowski &
Rock, 1983; Post-Beittenmiller et al, 1989). These results show
that impaired CoA biosynthesis induced by downregulation of
PANK2 in human cells is associated with a reduction of mtACP
which occurs independent of any detectable change in total
cellular CoA levels.
Discussion
Our results demonstrate that impairment of CoA biosynthesis leads
to decreased levels of 40-phosphopantetheinylated holo-mtACP,
which causes decreased levels of lipoylated, activated PDH.
◀ Figure 5. Downregulation of dPANK/fbl, dPPCDC/ppcdc, or mtacp in the Drosophila wing disc leads to blistering in the adult wing.dPANK/fbl, dPPCDC/ppcdc, or mtacp was downregulated using gene-specific RNAis during larval development in the wing pouch only (Appendix Fig S4). To enhance the
efficiency of the RNAi, experiments were also performed in the presence of the RNAi enhancer Dicer-2 (dcr2). Larvae and the emerging adult flies were raised at 29°C, unless
indicated otherwise. The wings of the adult flies were dissected and typical examples of the wings of the adult flies of the indicated genetic backgrounds are provided.
A Control adult wing.
B Control adult wing in a Dicer-2 genetic background.
C dPANK/fbl-RNAi adult wing.
D dPANK/fbl-RNAi adult wing in a Dicer-2 genetic background.
E dPPCDC/ppcdc-RNAi adult wing
F dPPCDC/ppcdc-RNAi adult wing in a Dicer-2 genetic background.
G Combined dPANK/fbl-RNAi and dPPCDC/ppcdc-RNAi adult wing.
H mtacp-RNAi adult wing. Larvae and flies were raised at 18°C due to decreased viability at 29°C.
I mtacp-RNAi adult wing in a Dicer-2 genetic background. Larvae and flies were raised at 18°C due to decreased viability at 29°C.
Data information: The wing blisters are visible as brown wrinkled tissue, in contrast to the transparent flat tissue of control wings. Arrow heads were used to mark the
perimeter of the blisters, which in some cases does equal the whole wing (F, G, I). Scale bars = 500 lm.
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Stimulation of PDH activity in the setting of CoA dyshomeostasis
rescued phenotypes ranging from viability to organ development,
suggesting that impaired PDH function is at least partly responsible
for the observed phenotypes. Our results implicate the linear path-
way proposed in Fig 2 to explain why impairment at individual
steps along this pathway results in overlapping phenotypes in both
the Drosophila wing model and in the human disorders PKAN,
CoPAN, MePAN, and PDH-E2 deficiency.
Here we show a specific and direct effect of impaired CoA biosyn-
thesis on PDH activity. Other enzyme complexes (aKGDH, BCKDH,
and GCV) that are regulated by lipoylation (Cronan, 2016) are
presumably affected as well, as indicated by decreased levels of pan-
lipoylated protein levels (Fig 3D, Appendix Fig S1). The rescue by
DCA and SIRT4 downregulation in Drosophila under CoA-compro-
mised conditions indicates that at least some of the defects can be
attributed to reduced PDH activity because boosting PDH activity
causes specific defects to revert to wild-type phenotypes. SIRT4
regulates PDH activity via its lipoamidase activity. This activity of
SIRT4 cleaves the lipoyl moiety from the E2 component of PDH and
inhibits PDH activity (Mathias et al, 2014) explaining the observed
rescue. In addition, SIRT4 also interacts with aKGDH-E2 and
BCKDH-E2 (Mathias et al, 2014). Therefore, it could be possible that
SIRT4 can negatively influence lipoylation of these other enzymes as
well. Therefore inhibition of SIRT4 would increase lipoylation of
aKGDH-E2, and BCKDH-E2 as well as of PDH-E2. Therefore recov-
ery of activity of one or more of these enzymes is likely to explain
the potent rescue observed after SIRT4 downregulation.
This rescue is somewhat surprising because boosting these
enzyme activities still does not resolve decreased CoA levels or
other effects of decreased levels of holo-mtACP. mtACP serves
numerous functions that are conserved across species. Indeed,
NDUFAB1, the human ortholog of mtACP, is a subunit of and
required for the assembly of complex I (Vinothkumar et al, 2014;
Van Vranken et al, 2018) and is involved in iron-sulfur biogenesis
(Van Vranken et al, 2016). It is possible that the majority of the
RNAi-induced phenotype in the Drosophila wing arises from
reduced PDH activity and not from other affected processes down-
stream from holo-mtACP.
Our results demonstrate that, under conditions of decreased
levels of total CoA such as in dPANK/fbl-downregulated S2 cells or
HoPAN-treated samples, levels of holo-mtACP are decreased. This
result is expected because CoA is the source for the 40-phosphopan-
tetheinylation and, by reducing its levels, the rate of posttransla-
tional modification that depends on this source would be expected
to decrease. A decrease in mtACP levels, most likely reflecting a
decrease in active 40-phosphopantetheinylated holo-mtACP, under
conditions of normal total CoA levels, as in the PANK2-depleted
human cells (Fig 7), is more challenging to explain. It is possible
that in subcellular compartments like mitochondria, which contain
PANK2 and COASY, CoA levels are decreased, inducing a reduction
of holo-mtACP. It also may be that PANK2 depletion “only” lowers
the rate of CoA de novo biosynthesis, which could trigger a compen-
satory mechanism inhibiting the formation of holo-mtACP since this
process consumes CoA. The reduction of a consumptive process
could explain the decrease in holo-mtACP and also could be recon-
ciled with the results showing that total CoA levels remain constant.
The prediction would be that under conditions of normal CoA levels
but reduced holo-mtACP, complex I activity and iron-sulfur cluster
formation would be decreased, which is in agreement with the
results of Jeong et al in their Pank2-depleted mouse model. This
further suggests that PKAN, and possibly also CoPAN, is caused by
a reduced rate of CoA biosynthesis and not by an actual decrease in
CoA levels. This is consistent with the findings that total CoA levels
in CoPAN patient fibroblasts are also not reduced (Dusi et al, 2014).
It is possible then that addition of 40-phosphopantetheine to Pank2-
depleted cells boosts the rate of CoA biosynthesis, thereby explain-
ing its rescuing potential, as reported by Jeong et al (2019).
Our hypothesis can explain some of the phenotypic similarities
and differences between PKAN, CoPAN, MePAN, and PDH-E2 defi-
ciency. All these disorders selectively damage the basal ganglia,
with most of the pathology localizing in globus pallidus. In PKAN
and CoPAN, iron accumulates in this structure, but this phenom-
enon is not observed in the other two disorders (Fig 8). This dif-
ference can be explained by postulating that the iron accumulation
stems from dysregulation of an intermediate downstream of PANK
and COASY but upstream of MECR and PDH-E2. A candidate inter-
mediate is again holo-mtACP; it was recently shown in eukaryotic
cells that holo-ACP is involved in iron-sulfur cluster biogenesis
and stability, highlighting a crucial additional role for the 40-
phosphopantetheine–conjugated mtACP (Van Vranken et al, 2016;
◀ Figure 6. Chemical and genetic inhibition of a PDH inactivator rescues the wing phenotypes induced by impaired CoA biosynthesis.A Experiments were performed as depicted in (C, left part) and the % of blistered wings was determined in adult dPPCDC/ppcdc-RNAi flies raised on control food or on
food containing increasing concentrations of DCA. A dose-dependent rescue was observed. Representative images of a blistered and a normal, non-blistered wing are
shown. Total number of flies scored for each group over several experiments is indicated above each bar. Statistical analysis was carried out using Fisher’s exact test.
B Schematic visualization of the pyruvate dehydrogenase complex (PDHc) and its negative regulators. The PDH complex consists of 3 subunits: PDH-E1, PDH-E2, and
PDH-E3. The PDH complex is required for the conversion of pyruvate to an acetyl group, subsequently forming acetyl-CoA. Lipoylation of PDH-E2 is required for
normal activation of PDH. Pyruvate dehydrogenase kinase (PDK) phosphorylates PDH-E1 and thereby inactivates PDH. Sirtuin 4 (SIRT4) is a hydrolase abrogating
lipoylation of PDH-E2 and thereby also inhibiting PDH activity. Dichloroacetic acid (DCA) inhibits PDK. Inhibiting PDK or SIRT4 expression by RNAi, or inhibiting PDK
by DCA is expected to increase activation of PDH.
C Schematic representation of experiments performed to investigate possible pharmacologic and genetic rescue of the adult wing-blister phenotype induced by
dPPCDC/ppcdc-RNAi. Left part: dPPCDC/ppcdc-RNAi flies were raised on control food or on food containing DCA and the number of blistered wings was scored. Right
part: Adult wing-blister phenotype of dPPCDC/ppcdc-RNAi flies were examined with dPPCDC/ppcdc-RNAi flies in which PDK-RNAi or SIRT4-RNAi were co-expressed, and
then the number of blistered wings were scored.
D Experiments were performed as depicted in (C, right part) and the % of adult blistered wings was determined for dPPCDC/ppcdc-RNAi flies alone or in a combined
background with PDK-RNAi or SIRT4-RNAi. Two independent RNAi lines were used to downregulate PDK and to downregulate SIRT4. Co-expression of RNAi constructs
that targeted PDK or SIRT4 resulted in rescue of the blister phenotype. Total number of flies scored for each group over several experiments is indicated above each
bar. Statistical analysis was carried out using Fisher’s exact test.
Data information: Scale bars in (A, D) = 500 lm.
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Cory et al, 2017). In Saccharomyces cerevisiae, loss of mtACP leads
to reduced iron-sulfur cluster formation, inactivation of iron-sulfur
cluster-dependent enzymes such as aconitase, and activation of
iron-responsive factors Aft1 and Aft2 (Van Vranken et al, 2016).
Consistently decreased iron-sulfur cluster levels result in mitochon-
drial iron overload (Chen et al, 2002). Abnormal iron homeostasis
and reduced aconitase activity are characteristics of PKAN patient
fibroblasts, as well as IPSC-derived neurons (Santambrogio et al,
2015; Orellana et al, 2016). Iron dyshomeostasis and reduced aconi-
tase activity are also reported by Jeong et al in their PKAN mouse
model (Jeong et al, 2019). This explains why mitochondrial iron
dyshomeostasis and accumulation resulting from mtACP dysfunc-
tion is observed in PKAN and CoPAN, diseases associated with steps
upstream of holo-mtACP, but not in MePAN and PDH-E2 deficien-
cies, diseases associated with steps downstream of holo-mtACP.
Consistent with this, we predict that MECR deficiency compromises
lipoic acid production without affecting mtACP levels or activity
(Fig 8). Recently, Klopstock et al (2019) reported that iron chelation
is effective in reducing the brain iron content in PKAN patients;
however, the pathway proposed here would predict that iron chela-
tion therapy alone would be insufficient to fully counteract neurode-
generation in patients with PKAN or CoPAN.
Our results and models complement and agree with the work of
Jeong et al and underscore the clinical relevance of our findings.
Jeong et al demonstrate, in a mouse model of PKAN, the presence
of a specific set of perturbations in the globus pallidus. These alter-
ations include: impaired complex I function with decreased oxida-
tive phosphorylation, impaired lipoic acid production with loss of
activity of a lipoylated enzyme (PDH), and iron dyshomeostasis
with loss of activity of dependent enzymes and processes
presumably from impaired iron-sulfur cluster biogenesis. All their
reported findings are consistent with a primary defect in 40-phospho-
pantetheinylated mtACP, including their observation of rescue of all
molecular changes in mouse globus pallidus by administration of 40-
phosphopantetheine.
Despite providing a compelling hypothesis and strong results to
support it, we recognize that the Drosophila model does not reflect
the full complexity of the mammalian system, especially regarding
the metabolic step compromised in PKAN. Downregulation of the
single dPANK/fbl gene in fruit flies evokes a more severe phenotype
compared to downregulation of only PANK2 in mammalian
systems. Alternative hypotheses to explain decreased activity of
PDH from a CoA metabolic defect should also be considered. One
attractive hypothesis is based on the process of CoAlation, a recently
identified posttranslational modification. A range of proteins was
identified, including PDK, that can be reversibly modified by cova-
lent attachment of CoA, which influences their activity. PDK activity
is inhibited by CoAlation (Tsuchiya et al, 2017). Therefore, an alter-
native explanation for our results may be that under conditions of
impaired CoA biosynthesis, levels of PDK-CoAlation are reduced,
leading to increased activity of PDK and therefore decreased activity
of PDH.
Our hypothesis does not explain why the globus pallidus is selec-
tively damaged in the four diseases. For PKAN, it may be that the
other PANKs compensate for the loss of PANK2 in areas outside the
globus pallidus; however, this redundancy does not exist for
CoPAN, MePAN, and PDH-E2 deficiency. Our hypothesis suggests
that the globus pallidus is vulnerable to decreased activity of PDH;
however, an explanation for this sensitivity is still lacking. The
PKAN mouse model reported by Jeong et al (2019) is a powerful
◀ Figure 7. Decreased levels of PANK2 are associated with decreased levels of mtACP in mammalian cells.A Western blot analysis of HEK293T cells cultured in vitamin B5-deprived medium. Samples of doxycycline-treated non-targeted controls (NTC) and inducible PANK2
knockout lines, PANK2.1 and PANK2.3, were run and probed for hPANK2 (the hPANK2-specific band is marked by a red arrow, a closely migrating background band is
marked by a blue arrow; see also Appendix Fig S10) and for mtACP. GAPDH was used as a control. A significant decrease in mtACP levels was detected in clone 2.3.
B Quantification of protein band intensities of Westerns shown in (A), performed with Image Studio Lite (LI-COR) and plotted as relative ratio of mtACP to GAPDH.
Mean  SD is given. One-tailed, unpaired Student’s t-test was performed to compare indicated subsets. n = 3 for all samples.
C As in (A) for SH-SY-5Y cells. A decrease in mtACP levels was detected in both hPANK2 depleted SH-SY-5Y clones.
D Quantification of protein band intensities of Westerns shown in (C), performed with Image Studio Light (LI-COR) and plotted as relative ratio of mtACP to GAPDH.
Mean  SD is given. One-tailed, unpaired Student’s t-test was performed to compare indicated subsets. n = 3 for all samples.
E, F Total CoA levels were measured using HPLC as described in Srinivasan et al (2015) in the indicated clones of the HEK293T cells (E) and SH-SY-5Y cells (F) after
10 days of RNAi treatment. HEK293T and SH-SY-5Y cells were cultured in vitamin B5-deprived medium. Mean  SD is given. n = 3 for all samples.
Source data are available online for this figure.
▸Figure 8. Phenotypic features of PKAN, CoPAN, MePAN, and PDH-E2 deficiency and their hierarchy on a pathophysiological axis.Left part: The names of the diseases PKAN, CoPAN, MePAN, and PDH-E2 deficiency are given in full with their corresponding OMIM numbers, clinical features, and
schematics of representative MR images (T2-weighted). Schematic drawing is provided to identify the relevant basal ganglia structures in healthy brain, including
putamen, caudate nucleus, and globus pallidi. In healthy brain, these structures appear isointense on T2-weighted imaging to surrounding gray matter until early
adulthood; in all four diseases, T2-hyperintense signal is seen in the globus pallidus bilaterally (McWilliam et al, 2010; Kruer et al, 2012; Dusi et al, 2014; Heimer et al,
2016), and in PKAN and CoPAN, pallidal signal hypointensity is also seen, which is indicative of high iron levels (indicated with an arrowhead). [Note that T2-
hyperintense putamina were also been observed in some MePAN patients (Heimer et al, 2016)].The pathway on the right of the figure consolidates the proposed
biochemical linkages, explaining how mutations in four different genes all result in PDH-E2 deficiency and thus lead to shared phenotypic features. From top to bottom:
pantothenate kinase (PANK), phosphopantothenoylcysteine synthetase (PPCS), phosphopantothenoylcysteine decarboxylase (PPCDC), and coenzyme A synthase (COASY)
are enzymes required for the de novo biosynthesis of CoA. Mitochondrial acyl carrier protein (mtACP) undergoes posttranslational modification, gaining a 40-
phosphopantetheine moiety that is derived from CoA in order to form the active holo-mtACP. Holo-mtACP is required for lipoylation of PDH-E2, a requirement for
activation of the PDH complex. We propose that a decrease in CoA biosynthesis leads to decreased amounts of holo-mtACP, decreased lipoylation of PDH-E2, and
decreased activity of PDH. holo-mtACP is also required for the biogenesis of iron-sulfur clusters. Impaired iron-sulfur cluster formation leads to iron dyshomeostasis.
Therefore, this model also explains iron accumulation in diseases associated with defects upstream of holo-mtACP but not in those downstream of holo-mtACP.
Arrowhead indicates iron accumulation in schematic drawing of PKAN and CoPAN.
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tool that may enable discovery of an answer to this important
question.
Our model presented in Fig 8, in combination with the results
provided by Jeong et al (2019) and Klopstock et al (2019), provides
suggestions for possible therapies for the four neurodegenerative
diseases. DCA is a blood–brain barrierpermeable drug (Abemayor
et al, 1984; Kuroda et al, 1984) that has been investigated as a
candidate therapeutic for metabolic diseases as well as cancer
(Stacpoole et al, 1992; Stacpoole et al, 2006; Michelakis et al, 2010;
Abdelmalak et al, 2013). Despite achieving biochemical remission
of lactic acidosis in a genetically heterogeneous cohort of children
with congenital lactic acidosis, DCA failed to slow neurological
decline (Stacpoole et al, 2006). Moreover, while DCA rescues the
Drosophila wing model, it would most likely not rescue iron
dyshomeostasis or other dysfunction arising downstream of holo-
mtACP such as of aconitase and complex I activities in PKAN and
CoPAN patients. Based on the results by Jeong et al, 40-phosphopan-
tetheine is the most promising therapeutic strategy for PKAN
because it restores an early step in the affected pathway and there-
fore would be predicted to prevent all downstream impaired
processes. In CoPAN patients, a CoA biosynthesis step is affected
downstream of 40-phosphopantetheine; therefore, we would not
expect 40-phosphopantetheine to prevent disease changes in CoPAN.
However, based on our proposed pathway, an iron chelator in
combination with DCA or a SIRT4 inhibitor may be beneficial in
CoPAN. Finally, DCA or a SIRT4 inhibitor may also be beneficial in
MePAN and to some extend in PDH-E2 deficiency, because DCA
addition will not rescue severe loss of function mutations. Addi-
tional investigations in mammalian models are required to substan-
tiate these ideas.
Materials and Methods
S2 cell culture, transfection, HOPAN, and CoA treatment
Drosophila Schneider’s S2 cells were maintained at standard condi-
tions as described previously (Srinivasan et al, 2015). Here, cells in
their exponential phase of growth were transfected (Effectene,
Qiagen) with the mtACP WT or mutant constructs listed below and
grown for 2 days.
HoPan and CoA or DCA treatment were done on S2 cells in their
exponential phase and treated with 0.5 mM HoPan in the presence
or absence of 100 lM CoA or 10 mM DCA. Cells were treated for 2,
4, or 7 days, and untreated S2 cells were used as control.
Cloning of mtACP (mutant) constructs
In order to overexpress wild-type or mutant mtACP, constructs were
created in the following manner. An mtACP cDNA clone for isoform
B was obtained from the Drosophila Genomics Resource Center
(AT22870; FBcl0025645) and multiplied by PCR using primers
flanked by EcoRI and XhoI restriction sites:
The pAc5.1 vector (Invitrogen) was digested using EcoRI and
XhoI and ligated with the mtacp PCR product. Competent cells were
transfected with the ligated construct and the purified construct was
sequenced to ensure its fidelity. Constructs overexpressing mutant
mtacp were subsequently created by site-directed mutagenesis of
this construct using mutagenesis primers (Q5 Site-directed Muta-
genesis Kit, New England Biolabs). The fidelity of the resulting
constructs was verified by sequencing. Primers sequences are
presented in Appendix Table S1.
Lentiviral transductions
Inducible lentiviral shRNA vectors targeting a non-targeted control
(NTC) or hPANK2 were obtained from Dharmacon (for sequences,
see supplementary data) and lentivirus was produced as previously
described (Schepers et al, 2007). 293T cells (ATCC CRL-3216) and
SH-SY5Y cells (ATCC CRL-2266) were transduced in 2 consecutive
rounds of 8–12 h with lentiviral supernatant supplemented with
10% FCS and polybrene (4 lg/ml; Sigma). Transduced 293T and
SH-SY5Y cells were selected in a medium containing 0.6 lg/ml or
0.2 lg/ml puromycin (Thermo Fischer Scientific), respectively, for
1 week.
FACS analysis
After 1 week of puromycin selection, expression of the microRNA-
TurboGFP cassette was induced with doxycycline (Sigma, concen-
trations ranging from 0 to 1.5 lg/ml) for 3 days and analyzed for
TurboGFP expression on an LSRII (Becton Dickinson) flow cytome-
ter, and data were analyzed using FlowJo software (FlowJo V10).
Inducible hPANK2 knockdown cells
Cells were produced as described above. HEK293T and SH-SY5Y
inducible hPank2 KD cells were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM, Sigma) supplemented with 10% fetal
bovine serum (FBS, Greiner Bio-one) and antibiotics (penicillin/
streptomycin, Invitrogen) in 5% CO2 at 37°C. Induction of the
microRNA-TurboGFP in SH-SY5Y was done with 0.5 lg/ml doxycy-
cline for 7 days. Induction of the microRNA-TurboGFP in HEK293T
was done with 1 lg/ml doxycycline for 14 days, in custom made
DMEM without vitamin B5 (Thermo Scientific) supplemented with
dialyzed FBS (Thermo Scientific) and antibiotics. HoPan treatment
(0.25 mM) was done from day 7 till day 14.
A complete list of vectors used, commercially available cell lines,
and lines created in this publication can be found in
Appendix Tables S1 and S2. The cell lines were regularly visually
inspected and tested negative for mycoplasma contamination.
Western blot analysis and antibodies
For Western blot analysis, cells were dissolved in 2× Laemli buffer,
sonificated, and boiled for 5 min with 5% b-mercaptoethanol
(Sigma). Protein concentration was determined using DC protein
assay (Bio-Rad). Equal amounts of protein (10–30 lg) were loaded
on a 10, 12, or 4–20% gradient gel (Bio-Rad), and transferred onto
PVDF membranes using the Trans Blot Turbo System (Bio-Rad).
Membranes were blocked in 5% fat-free milk for 1 h at room
temperature, and then rinsed in PBS-Tween 20. Incubations with
primary antibodies were done overnight at 4°C followed by incuba-
tions with HRP-conjugated secondary antibodies (Amersham
1:5,000) for 1.5 h at room temperature. Detection was performed
using ECL reagent (Thermoscientific) and visualized using the
16 of 21 EMBO Molecular Medicine e10488 | 2019 ª 2019 The Authors
EMBO Molecular Medicine Roald A Lambrechts et al
ChemiDoc imager (Bio-Rad). The following primary antibodies were
used: anti-mtACP antibody (Abcam, 1:1,000), anti-lipoic acid (Mer-
ck, 1:1,000), anti-PDH-E2 (Abcam, 1:1,000), anti-a-Tubulin (Sigma,
1:5,000), anti-GAPDH (Fitzgerald, 1:10,000), anti-dPank/Fbl
(Bosveld et al, 2008; 1:1,000), and anti-hPANK2 (Origene 1:500). A
complete list of antibodies used can be found in Appendix Table S3.
PDH activity measurements
S2 cells were cultured as described above for 4 days in control
medium or medium containing 500 lM HoPan. Cells were pelleted at
approximately 106 cells/pellet and washed once with PBS, and later
pyruvate dehydrogenase complex activity was measured using the
Pyruvate Dehydrogenase Activity Colorimetric Assay Kit (Cat#K679-
100, BioVision) according to manufacturer’s instructions. Three
biological replicates were used per measurement, with each biologi-
cal replicate measured in (technical) triplicate. Protein concentration
was determined using BCA Protein Assay Kit (ThermoScientific)
according to manufacturer’s instructions. All measurements were
recorded using a VarioSkan Lux plate reader; analysis was performed
with GraphPad (see section “Statistical analysis”).
Drosophila maintenance and genetics
Drosophila melanogaster stocks were maintained on standard corn-
meal agar fly food (containing water, agar 17 g/l, sugar 54 g/l, yeast
extract 26 g/l, and nipagin 1.3 g/l) at 22°C. Crosses were raised at
various temperatures as indicated in the text/legends. The stocks
were either obtained from the Bloomington Stock Centre (Indiana
University, USA) or the VDRC (Vienna Drosophila RNAi Collection,
Vienna, Austria).
Stocks used for this project
A complete list of commercially available fly lines, lines created in
the context of this publication, and detailed genotypes can be found
in Appendix.
Crosses were raised at various temperatures as indicated in the
text/legends.
Validation of UAS-dPANK/fbl-RNAi and UAS-dPPCDC/ppcdc-RNAi
lines by meiotic recombination
Based on previous results (expression with various drivers, data not
shown), we predicted that our UAS-dPANK/fbl-RNAi (#101437) and
UAS-dPPCDC/ppcdc-RNAi (#104495) KK lines, obtained from the
VDRC, might contain not only the regular RNAi transgene at loca-
tion 30B, but an additional one at 40D, which has been shown to
act as a phenotypical enhancer and able to cause false-positive
results, especially when combined with ubiquitous or wing drivers
(Green et al, 2014; Vissers et al, 2016).
To test those lines for RNAi transgene integration site occupancy,
we used genomic DNA preparation, followed by PCR analysis, as
described previously (Vissers et al, 2016). When both lines were
confirmed to carry transgenes at integration sites 30B and 40D, we
employed meiotic recombination to remove the one at 40D. Lines
with the remaining insertion at 30B were confirmed by
PCR (Appendix Fig S1A) and tested for knockdown by
immunohistochemistry (anti-Fbl, Fig 4A) and qPCR (fbl and PPCDC,
Appendix Fig S1B and C). The “30B-only” cleaned-up lines were
used for all experiments presented in this publication unless stated
specifically otherwise (also see stock list in the Appendix for details).
Immunofluorescence analysis of Drosophila wing imaginal discs
For immunofluorescence of Drosophila wing discs, the crosses were
raised at 29°C (MS1096-GAL4; UAS-GFP × UAS-GFP as control or x
UAS-dPANK/fbl-RNAi) or 22°C (MS1096-GAL4; UAS-GFP × UAS-GFP
as control or x UAS-mtacp-RNAi #29528). Wandering L3 larvae (day
5) were collected and their wing discs dissected in ice-cold phos-
phate-buffered saline (PBS). The discs were fixed with 4% formalde-
hyde (Thermo Scientific Pierce) for 30 min, washed for 3 × 20 min
with phosphate-buffered saline (PBS) + 0.1% Triton X-100 (Sigma
Aldrich), and afterward incubated in primary antibody rabbit anti-
Fbl (Bosveld et al, 2008; 1:500) or rabbit anti-mtACP (ThermoFisher
PA5-22191, 1:500) in PBS + 0.1% Triton X-100 overnight to visual-
ize the presence/absence/localization of Fbl or mtACP. After an
additional washing step of 3 × 20 min in PBS + 0.1% Triton X-100,
the discs were incubated in secondary goat anti-rabbit-Alexa488 anti-
body (Molecular Probes) for 2 h at room temperature. DAPI (0.2 lg/
ml; Thermo Scientific) was used to visualize DNA. Finally, the
samples were mounted in 80% glycerol and analyzed using a Zeiss-
LSM780 NLO confocal microscope with Zeiss software. Adobe
Photoshop and Illustrator (Adobe Systems Incorporated, San Jose,
California, USA) were used for image assembly. A complete list of
antibodies used can be found in Appendix Table S3.
Drosophila survival rate experiments
Virgin female Actin-GAL4/CyO flies were crossed with males of
either UAS-GFP or UAS-dPANK/fbl-RNAi at 29°C on standard fly
food, or food supplemented with either sodium dichloroacetate
(DCA, Sigma) or pantethine (Pan, Sigma) at indicated concentra-
tions. The flies were allowed to lay eggs for 5 days, after which the
adults were discarded. The emerging adult (eclosing) male flies
were evaluated for the presence or absence of the CyO dominant
marker. Non-CyO flies were selected because only in these flies the
dPANK/fbl-RNAi (Actin-GAL4/UAS-dPANK/fbl-RNAi) or the GFP
(Actin-GAL4/UAS-GFP, as control) is expressed. Progeny were
counted daily over a period of 5 days to evaluate the total survival
rate of the adult flies. To determine the survival rate of dPANK/fbl-
RNAi flies, which is an indicator for the viability, the number of
male Actin-GAL4/UAS-dPANK/fbl-RNAi flies was divided by the total
number of male flies (CyO and non-CyO). At least 6 separate vials
containing offspring were used per condition.
Mounting and imaging of adult fly wings
To image wings of adult flies from various crosses, F1 males or
females of the indicated genotypes were collected for a period of
3 days and kept for an additional 2–3 days after eclosion to allow
for optimal unfolding and clearance of the wings. Afterward, they
were transferred into 70% ethanol and stored for at least 2–3 days.
The wings were removed with tweezers, mounted on slides in 80%
glycerol, and imaged with a light microscope (Olympus BX-50) at 2×
magnification. Adobe Photoshop and Illustrator (Adobe Systems
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Incorporated, San Jose, California, USA) were used for visual-
ization.
Pharmacological and genetic rescue of dPPCDC/ppcdc-RNAi-
induced wing blisters
For the pharmacological rescue, MS1096-GAL4, UAS-GFP or
MS1096-GAL4, and UAS-dPPCDC/ppcdc-RNAi females were crossed
with UAS-GFP males at 29°C on standard fly food, or food supple-
mented with sodium dichloroacetate (DCA, Sigma) at indicated
concentrations.
For the genetic rescue, MS1096-GAL4, UAS-GFP or MS1096-GAL4,
and UAS-dPPCDC/ppcdc-RNAi females were crossed with UAS-GFP,
UAS-PDK-RNAi (#28635 and #35142), or UAS-SIRT4-RNAi (#33984
and #36588) males at 29°C on standard fly food.
The females were allowed to lay eggs for 5 days, after which the
parents were discarded. F1 males were collected and imaged
as described above and analyzed for the presence or absence of
“blisters”.
The adult Drosophila wing consists of two layers, a dorsal (up-
per) and a ventral (lower) one, which are tightly connected to each
other (by adhesion molecules). “Blistering” of the wing has been
described in general as a condition in which dorsal and ventral wing
surfaces separate to form a hemolymph-filled blister (Martin et al,
1999). After mounting and imaging, they appear transparent and the
remains of the blister are only detectable by their crinkled surface
(Fig 5D and E). In blisters that encompass the whole wing, hemo-
lymph (and associated cell debris) is not cleared sufficiently and
after mounting and imaging these wings appear inflated with
brownish discolorations (Fig 5F–I).
Arrow heads were used to mark the perimeter of the blisters,
which in some cases does equal the whole wing. In comparison,
wings were scored as “not blistered”, if they appeared flat, struc-
turally normal, and/or no discoloration was observed (Fig 5A and
B). For visualization and quantification, images were recorded,
using Adobe Photoshop and Illustrator (Adobe Systems Incorpo-
rated, San Jose, California, USA) and GraphPad Prism software
(GraphPad Software, San Diego, CA, USA). For randomly chosen
experiments, the amount of blisters was counted by independent
researchers. Blinding was not performed.
qPCR
For quantitative real-time PCR (qPCR), we collected 8 specimens
from fly samples, in most cases adult flies, from crosses of Actin-
GAL4 with UAS-dPANK/fbl-RNAi F10 and F20, UAS-dPPCDC/ppcdc-
RNAi P7 and P17, UAS-PDK-RNAi #28635 and #35142, and UAS-
SIRT4-RNAi #333984 and #36588. The cross of Actin-GAL4 with
both UAS-dPPCDC/ppcdc-RNAis results in mid- to late-pupal lethal-
ity, so we collected those samples during pupal development. The
samples were crushed with a motor pestle, lysed in Trizol (Life
Technologies), and RNA isolation was performed according to stan-
dard protocol. The isolated RNA was treated with Turbo DNAse
(Ambion) followed by addition of random primers and reverse tran-
scription using M-MLV (Invitrogen). Quantitative PCR was
performed using Sybr Green (Bio-Rad) on a CFX Connect Real Time
System (Bio-Rad). Quantitative PCR was performed using primer
sets to detect dPANK/fbl, dPPCDC/ppcdc, PDK, and SIRT4 mRNA
expression, and normalized against Rp49 mRNA-loading controls.
qPCR was performed in the human cells to determine PANK1-4
levels. ells were collected and lysed in RLT and RNA isolation was
performed using the RNeasy kit from Qiagen according to the manu-
facturer’s instructions. Fly samples were normalized for rp49, and
human samples were normalized for B2M and UBC.
A complete list of qPCR primers can be found in
Appendix Table S2.
Statistical analysis
Densitometry and statistical analysis
Western blot analyses were measured using Image Studio Lite
(Li-Cor, www.licor.com/bio/image-studio-lite). Statistical analyses
were performed using Excel 2016 or GraphPad PRISM 5 (San Diego,
CA, USA), with either unpaired Student’s t-test or Fisher’s exact test.
Statistically significant results are depicted within each figure.
Unless stated specifically in the figure legend, all the data were
presented as mean  SD.
For proportional data, power calculations for comparing propor-
tions were used. F-tests were used to test if variances of the tested
populations were equal. The number of flies assured a statistical
power of 0.8 with a confidence level of 0.95 for Fisher’s exact test
and Student’s t-tests (proportional power calculations; Wang &
Chow, 2007), taking into account that the expected proportion of
responders is around 25–80%.
Expanded View for this article is available online.
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